Chemokine C-C motif receptor 5 and C-C motif ligand 5 promote cancer cell migration under hypoxia

Cancer Science

Volumn 103, Issue 5, 2012, Pages 904-912

  Lin, Sensen ^a   Wan, Shuying ^a   Sun, Li ^a   Hu, Jialiang ^a   Fang, Dongdong ^a   Zhao, Renping ^b   Yuan, Shengtao ^a   Zhang, Luyong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LUCIFERASE; MESSENGER RNA; RANTES;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CELL; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CLINICAL ARTICLE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOFLUORESCENCE; LYMPH NODE METASTASIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; RNA STABILITY; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CCL5; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LYMPHATIC METASTASIS; MIDDLE AGED; RECEPTORS, CCR5; RNA INTERFERENCE; TRANSFECTION;

EID: 84860251782     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02259.x     Document Type: Article

References (29)

1. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18: 217-42.
2. Samson M, Labbe O, Mollereau C, Vassart G, Parmentier M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 1996; 35: 3362-7.
3. Zlotnik A, Yoshie O, Nomiyama H. The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol 2006; 7: 243.
4. Karnoub AE, Dash AB, Vo AP et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449: 557-63.
5. Borczuk AC, Papanikolaou N, Toonkel RL et al. Lung adenocarcinoma invasion in TGFβRII-deficient cells is mediated by CCL5/RANTES. Oncogene 2008; 27: 557-64.
6. Aldinucci D, Lorenzon D, Cattaruzza L et al. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer 2008; 122: 769-76.
7. Vaday GG, Peehl DM, Kadam PA, Lawrence DM. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 2006; 66: 124-34.
8. Murooka TT, Rahbar R, Fish EN. CCL5 promotes proliferation of MCF-7 cells through mTOR-dependent mRNA translation. Biochem Biophys Res Commun 2009; 387: 381-6.
9. + T cells. Cancer Res 2011; 71: 5455-66.
10. Nesbeth Y, Scarlett U, Cubillos-Ruiz J et al. CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion. Cancer Res 2009; 69: 6331-8.
11. Conforti R, Ma Y, Morel Y et al. Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res 2010; 70: 490-500.
12. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002; 8: S62-7.
13. Liang Z, Wu T, Lou H et al. Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res 2004; 64: 4302-8.
14. Moriuchi H, Moriuchi M, Fauci AS. Cloning and analysis of the promoter region of CCR5, a coreceptor for HIV-1 entry. J Immunol 1997; 159: 5441-9.
15. Lin S, Sun L, Hu J et al. Chemokine C-X-C motif receptor 6 contributes to cell migration during hypoxia. Cancer Lett 2009; 279: 108-17.
16. Qin XF, An DS, Chen IS, Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 2003; 100: 183-8.
17. Sun HL, Liu YN, Huang YT et al. YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-κB signaling to HIF-1α accumulation during hypoxia. Oncogene 2007; 26: 3941-51.
18. Aubert S, Fauquette V, Hémon B et al. MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression. Cancer Res 2009; 69: 5707-15.
19. Kizaka-Kondoh S, Inoue M, Harada H, Hiraoka M. Tumor hypoxia: a target for selective cancer therapy. Cancer Sci 2003; 94: 1021-8.
20. Lu X, Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 2010; 16: 5928-35.
21. Finger EC, Giaccia AJ. Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev 2010; 29: 285-93.
22. Bosco MC, Puppo M, Santangelo C et al. Hypoxia modifies the transcriptome of primary human monocytes: modulation of novel immune-related genes and identification of CC-chemokine ligand 20 as a new hypoxia-inducible gene. J Immunol 2006; 177: 1941-55.
23. Bosco MC, Reffo G, Puppo M, Varesio L. Hypoxia inhibits the expression of the CCR5 chemokine receptor in macrophages. Cell Immunol 2004; 228: 1-7.
24. Mancino A, Schioppa T, Larghi P et al. Divergent effects of hypoxia on dendritic cell functions. Blood 2008; 112: 3723-34.
25. Copple BL, Bai S, Burgoon LD, Moon JO. Hypoxia-inducible factor-1alpha regulates the expression of genes in hypoxic hepatic stellate cells important for collagen deposition and angiogenesis. Liver Int 2011; 31: 230-44.
26. Opdenakker G, Van Damme J. The countercurrent principle in invasion and metastasis of cancer cells. Recent insights on the roles of chemokines. Int J Dev Biol 2004; 48: 519-27.
27. Gijsbers K, Geboes K, Van Damme J. Chemokines in gastrointestinal disorders. Curr Drug Targets 2006; 7: 47-64.
28. Biswas SK, Gangi L, Paul S et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages: defective NF-κB and enhanced IRF-3/STAT1 activation. Blood 2006; 107: 2112-22.
29. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008; 371: 771-83.